Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
This article was originally published in Scrip
Executive Summary
Alkermes is "excited and surprised" about the positive, and rapid, top-line results from a Phase I/II study of the company’s novel compound ALKS-5461 – using an approach of opiate receptor modulation – for major depressive disorder in patients who have had an inadequate response to standard therapies for clinical depression. The positive data now accelerates immediate initiation of a Phase II study, Richard Pops, chief executive of the company, told Scrip.